Policy | July 07, 2025
Dr. Jitendra Singh inaugurates 'National Biobank' at CSIR-IGIB
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability
Viatel bioresorbable polymers are increasingly used in dental and orthopedic implants
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Subscribe To Our Newsletter & Stay Updated
